newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA